CRLBF
Price
$1.28
Change
+$0.03 (+2.40%)
Updated
Dec 24 closing price
Capitalization
454.38M
82 days until earnings call
Intraday BUY SELL Signals
TCNNF
Price
$8.10
Change
+$0.26 (+3.32%)
Updated
Dec 24 closing price
Capitalization
1.54B
62 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRLBF vs TCNNF

Header iconCRLBF vs TCNNF Comparison
Open Charts CRLBF vs TCNNFBanner chart's image
Cresco Labs
Price$1.28
Change+$0.03 (+2.40%)
Volume$580.92K
Capitalization454.38M
Trulieve Cannabis
Price$8.10
Change+$0.26 (+3.32%)
Volume$185.84K
Capitalization1.54B
CRLBF vs TCNNF Comparison Chart in %
CRLBF
Daily Signal:
Gain/Loss:
TCNNF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRLBF vs. TCNNF commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRLBF is a StrongBuy and TCNNF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (CRLBF: $1.28 vs. TCNNF: $8.10)
Brand notoriety: CRLBF and TCNNF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRLBF: 41% vs. TCNNF: 19%
Market capitalization -- CRLBF: $454.38M vs. TCNNF: $1.54B
CRLBF [@Pharmaceuticals: Generic] is valued at $454.38M. TCNNF’s [@Pharmaceuticals: Generic] market capitalization is $1.54B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRLBF’s FA Score shows that 0 FA rating(s) are green whileTCNNF’s FA Score has 1 green FA rating(s).

  • CRLBF’s FA Score: 0 green, 5 red.
  • TCNNF’s FA Score: 1 green, 4 red.
According to our system of comparison, TCNNF is a better buy in the long-term than CRLBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRLBF’s TA Score shows that 6 TA indicator(s) are bullish while TCNNF’s TA Score has 6 bullish TA indicator(s).

  • CRLBF’s TA Score: 6 bullish, 4 bearish.
  • TCNNF’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both CRLBF and TCNNF are a good buy in the short-term.

Price Growth

CRLBF (@Pharmaceuticals: Generic) experienced а -33.19% price change this week, while TCNNF (@Pharmaceuticals: Generic) price change was -27.18% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.98%. For the same industry, the average monthly price growth was +12.50%, and the average quarterly price growth was +30.15%.

Reported Earning Dates

CRLBF is expected to report earnings on Mar 18, 2026.

TCNNF is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+5.98% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TCNNF($1.54B) has a higher market cap than CRLBF($454M). TCNNF YTD gains are higher at: 56.265 vs. CRLBF (40.085). TCNNF has higher annual earnings (EBITDA): 322M vs. CRLBF (112M). TCNNF has more cash in the bank: 449M vs. CRLBF (45.4M). CRLBF has less debt than TCNNF: CRLBF (581M) vs TCNNF (813M). TCNNF has higher revenues than CRLBF: TCNNF (1.19B) vs CRLBF (670M).
CRLBFTCNNFCRLBF / TCNNF
Capitalization454M1.54B29%
EBITDA112M322M35%
Gain YTD40.08556.26571%
P/E RatioN/AN/A-
Revenue670M1.19B56%
Total Cash45.4M449M10%
Total Debt581M813M71%
FUNDAMENTALS RATINGS
CRLBF vs TCNNF: Fundamental Ratings
CRLBF
TCNNF
OUTLOOK RATING
1..100
3150
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
3536
P/E GROWTH RATING
1..100
10015
SEASONALITY SCORE
1..100
5034

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRLBF's Valuation (81) in the null industry is in the same range as TCNNF (81). This means that CRLBF’s stock grew similarly to TCNNF’s over the last 12 months.

CRLBF's Profit vs Risk Rating (100) in the null industry is in the same range as TCNNF (100). This means that CRLBF’s stock grew similarly to TCNNF’s over the last 12 months.

TCNNF's SMR Rating (94) in the null industry is in the same range as CRLBF (95). This means that TCNNF’s stock grew similarly to CRLBF’s over the last 12 months.

CRLBF's Price Growth Rating (35) in the null industry is in the same range as TCNNF (36). This means that CRLBF’s stock grew similarly to TCNNF’s over the last 12 months.

TCNNF's P/E Growth Rating (15) in the null industry is significantly better than the same rating for CRLBF (100). This means that TCNNF’s stock grew significantly faster than CRLBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRLBFTCNNF
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
78%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 19 days ago
89%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CRLBF
Daily Signal:
Gain/Loss:
TCNNF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DCCIX31.120.16
+0.52%
Nomura Small Cap Core I
GCVTX24.970.10
+0.40%
Goldman Sachs Large Cp Val Insghts Inv
FHKIX53.740.15
+0.28%
Fidelity Advisor China Region I
FFTYX4.190.01
+0.24%
AB Sustainable US Thematic Advisor
GSZPX31.520.03
+0.10%
Goldman Sachs Small Cap Gr Insghts P

CRLBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRLBF has been closely correlated with TSNDF. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRLBF jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRLBF
1D Price
Change %
CRLBF100%
+2.40%
TSNDF - CRLBF
76%
Closely correlated
+4.46%
CURLF - CRLBF
76%
Closely correlated
-2.20%
TCNNF - CRLBF
75%
Closely correlated
+3.32%
JUSHF - CRLBF
74%
Closely correlated
-3.80%
GTBIF - CRLBF
72%
Closely correlated
+5.03%
More

TCNNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, TCNNF has been closely correlated with GTBIF. These tickers have moved in lockstep 83% of the time. This A.I.-generated data suggests there is a high statistical probability that if TCNNF jumps, then GTBIF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCNNF
1D Price
Change %
TCNNF100%
+3.32%
GTBIF - TCNNF
83%
Closely correlated
+5.03%
CURLF - TCNNF
80%
Closely correlated
-2.20%
TSNDF - TCNNF
76%
Closely correlated
+4.46%
CRLBF - TCNNF
75%
Closely correlated
+2.40%
JUSHF - TCNNF
73%
Closely correlated
-3.80%
More